Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation Journal Article


Authors: Yegya-Raman, N.; Ho Lee, S.; Friedes, C.; Wang, X.; Iocolano, M.; Kegelman, T. P.; Duan, L.; Li, B.; Berlin, E.; Kim, K. N.; Doucette, A.; Denduluri, S.; Levin, W. P.; Cengel, K. A.; Cohen, R. B.; Langer, C. J.; Kevin Teo, B. K.; Zou, W.; O'Quinn, R. P.; Deasy, J. O.; Bradley, J. D.; Sun, L.; Ky, B.; Xiao, Y.; Feigenberg, S. J.
Article Title: Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation
Abstract: Purpose: We assessed the association of cardiac radiation dose with cardiac events and survival post-chemoradiation therapy (CRT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) after adoption of modern radiation therapy (RT) techniques, stricter cardiac dose constraints, and immune checkpoint inhibitor (ICI) consolidation. Methods and Materials: This single-institution, multi-site retrospective study included 335 patients with LA-NSCLC treated with definitive, concurrent CRT between October 2017 and December 2021. All patients were evaluated for ICI consolidation. Planning dose constraints included heart mean dose < 20 Gy (<10 Gy if feasible) and heart volume receiving ≥ 50 Gy (V50Gy) < 25 %. Twenty-one dosimetric parameters for three different cardiac structures (heart, left anterior descending coronary artery [LAD], and left ventricle) were extracted. Primary endpoint was any major adverse cardiac event (MACE) post-CRT, defined as acute coronary syndrome, heart failure, coronary revascularization, or cardiac-related death. Secondary endpoints were: grade ≥ 3 cardiac events (per CTCAE v5.0), overall survival (OS), lung cancer-specific mortality (LCSM), and other-cause mortality (OCM). Results: Median age was 68 years, 139 (41 %) had baseline coronary heart disease, and 225 (67 %) received ICI consolidation. Proton therapy was used in 117 (35 %) and intensity-modulated RT in 199 (59 %). Median LAD V15Gy was 1.4 % (IQR 0–22) and median heart mean dose was 8.7 Gy (IQR 4.6–14.4). Median follow-up was 3.3 years. Two-year cumulative incidence of MACE was 9.5 % for all patients and 14.3 % for those with baseline coronary heart disease. Two-year cumulative incidence of grade ≥ 3 cardiac events was 20.4 %. No cardiac dosimetric parameter was associated with an increased risk of MACE or grade ≥ 3 cardiac events. On multivariable analysis, cardiac dose (LAD V15Gy and heart mean dose) was associated with worse OS, driven by an association with LCSM but not OCM. Conclusions: With modern RT techniques, stricter cardiac dose constraints, and ICI consolidation, cardiac dose was associated with LCSM but not OCM or cardiac events in patients with LA-NSCLC. © 2023 Elsevier B.V.
Keywords: adult; cancer survival; controlled study; aged; middle aged; major clinical study; overall survival; intensity modulated radiation therapy; cisplatin; advanced cancer; paclitaxel; radiation dose; positron emission tomography; follow up; carboplatin; etoposide; lung cancer; medical record review; retrospective study; cancer mortality; immunotherapy; dosimetry; radiation dose fractionation; cardiovascular risk; heart failure; cardiotoxicity; comorbidity; contrast medium; pemetrexed; heart; ischemic heart disease; chemoradiotherapy; cone beam computed tomography; non small cell lung cancer; cumulative incidence; nsclc; heart volume; proton therapy; acute coronary syndrome; heart left ventricle; immune checkpoint inhibitor; Common Terminology Criteria for Adverse Events; cardiovascular mortality; consolidation chemotherapy; four dimensional computed tomography; human; male; female; article; heart muscle revascularization; durvalumab; major adverse cardiac event; left anterior descending coronary artery; cardiac dosimetry
Journal Title: Radiotherapy and Oncology
Volume: 190
ISSN: 0167-8140
Publisher: Elsevier Inc.  
Date Published: 2024-01-01
Start Page: 110005
Language: English
DOI: 10.1016/j.radonc.2023.110005
PUBMED: 37972736
PROVIDER: scopus
PMCID: PMC11288624
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Joseph Owen Deasy
    524 Deasy